Despite the significant antifibrotic effects of the aforementioned substances in vivo and in vitro, the use of AT1 and ACE1 blockers alone did not sufficiently suppress CKD progression, in contrast to their combination. This evidence concerns the gene AGTR1 and chronic kidney disease.